USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 10,660 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $125.46, for a total value of $1,337,403.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Daniel A. Macuga also recently made the following trade(s):
- On Friday, July 27th, Daniel A. Macuga sold 503 shares of USANA Health Sciences stock. The shares were sold at an average price of $132.40, for a total value of $66,597.20.
Shares of USANA Health Sciences stock traded down $1.95 on Friday, hitting $113.52. The company’s stock had a trading volume of 107,199 shares, compared to its average volume of 158,468. USANA Health Sciences, Inc. has a 1 year low of $57.85 and a 1 year high of $137.95. The firm has a market cap of $2.92 billion, a PE ratio of 27.96 and a beta of 0.61.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, July 24th. The company reported $1.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.25. USANA Health Sciences had a return on equity of 29.50% and a net margin of 7.16%. The firm had revenue of $301.50 million during the quarter, compared to analyst estimates of $278.41 million. During the same quarter in the previous year, the business earned $0.98 EPS. USANA Health Sciences’s revenue for the quarter was up 17.3% compared to the same quarter last year. Sell-side analysts anticipate that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in USNA. Wells Fargo & Company MN increased its stake in shares of USANA Health Sciences by 5.8% in the 1st quarter. Wells Fargo & Company MN now owns 110,701 shares of the company’s stock valued at $9,509,000 after purchasing an additional 6,033 shares in the last quarter. SG Americas Securities LLC purchased a new stake in USANA Health Sciences during the 1st quarter worth approximately $137,000. DekaBank Deutsche Girozentrale increased its stake in USANA Health Sciences by 239.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 27,072 shares of the company’s stock worth $2,345,000 after buying an additional 19,099 shares in the last quarter. Mackay Shields LLC purchased a new stake in USANA Health Sciences during the 1st quarter worth approximately $3,780,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in USANA Health Sciences during the 1st quarter worth approximately $236,000. Hedge funds and other institutional investors own 56.38% of the company’s stock.
Separately, Pivotal Research restated a “hold” rating and issued a $135.00 price target on shares of USANA Health Sciences in a research note on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. USANA Health Sciences has a consensus rating of “Hold” and an average price target of $135.00.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.